The most common AE was alteration in liver-function studies (i.e., elevated ALT and AST and hyperbilirubinemia) [68,70,71,72,73,75,76,77,78], but whether AE was more likely to occur in patients receiving tocilizumab remains controversial [77,79]. The gene discussed is GPT; the disease is Hyperbilirubinemia.